Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 5

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 of profit or loss is the Company’s consolidated net income (loss). Consolidated asset information for the Company’s single-segment is presented in the Company’s consolidated Balance Sheet.

The following table sets forth significant research and development (“ R& D”) expenses by program as regularly provided to the CODM (in thousands):

                            Three Months Ended                                        Nine Months Ended                            
                            September 30,                                             September 30,                                
                            2025                                2024                  2025                                         
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Birtamimab (NEOD001)      $                        7,136      $         18,159      $                       52,483       60,908  
  PRX012                                            14,653                28,093                              47,821       97,900  
  PRX019                                             2,192                 1,328                               6,118        2,785  
  Other R& D                                         4,957                 3,143                              13,844       10,754  
  Total R& D                $                       28,938      $         50,723      $                      120,266      172,347  

Recent Accounting Pronouncements

On November 4, 2024, the Financial Accounting Standards Board (“ FASB”) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement line items in a tabular format in the notes to the financial statements. This guidance will be effective for the Company’s annual period ending December 31, 2027, and interim periods beginning January 1, 2028. Early adoption is permitted. Entities may

apply the guidance prospectively or retrospectively. The Company is currently evaluating the impact of this new standard on its financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public business entities to disclose a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the expected tax further broken out by nature and/or jurisdiction. The guidance also requires all entities to disclose income taxes paid, net of